Literature DB >> 17483248

Response of refractory immune thrombocytopenic purpura in a patient with common variable immunodeficiency to treatment with rituximab.

T M El-Shanawany1, P E Williams, S Jolles.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17483248      PMCID： PMC1955045          DOI： 10.1136/jcp.2006.041426

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  13 in total

1.  Common variable immunodeficiency: clinical and immunological features of 248 patients.

Authors:  C Cunningham-Rundles; C Bodian
Journal:  Clin Immunol       Date:  1999-07       Impact factor: 3.969

2.  Efficiency of rituximab in the treatment of autoimmune thrombocytopenic purpura associated with common variable immunodeficiency.

Authors:  M Mahévas; L Le Page; V Salle; R Cevallos; A Smail; P Duhaut; J P Ducroix
Journal:  Am J Hematol       Date:  2006-08       Impact factor: 10.047

3.  Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment.

Authors:  Julie Wang; Joseph M Wiley; Ruth Luddy; Jay Greenberg; Michael A Feuerstein; James B Bussel
Journal:  J Pediatr       Date:  2005-02       Impact factor: 4.406

4.  Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia.

Authors:  M Faurschou; H C Hasselbalch; O J Nielsen
Journal:  Eur J Haematol       Date:  2001-06       Impact factor: 2.997

5.  Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies).

Authors:  M E Conley; L D Notarangelo; A Etzioni
Journal:  Clin Immunol       Date:  1999-12       Impact factor: 3.969

Review 6.  Anti B cell therapy (rituximab) in the treatment of autoimmune diseases.

Authors:  Hanadi Kazkaz; David Isenberg
Journal:  Curr Opin Pharmacol       Date:  2004-08       Impact factor: 5.547

7.  Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses.

Authors:  S Kumar; F E Diehn; M A Gertz; A Tefferi
Journal:  Ann Hematol       Date:  2002-06-05       Impact factor: 3.673

8.  Delayed-onset neutropenia associated with rituximab therapy.

Authors:  Kritika Chaiwatanatorn; Newton Lee; Andrew Grigg; Robin Filshie; Frank Firkin
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

9.  The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.

Authors:  Nichola Cooper; Roberto Stasi; Susanna Cunningham-Rundles; Michael A Feuerstein; John P Leonard; Sergio Amadori; James B Bussel
Journal:  Br J Haematol       Date:  2004-04       Impact factor: 6.998

Review 10.  Use of rituximab, the new FDA-approved antibody.

Authors:  G A Leget; M S Czuczman
Journal:  Curr Opin Oncol       Date:  1998-11       Impact factor: 3.645
View more
  4 in total

1.  Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients.

Authors:  Delphine Gobert; James B Bussel; Charlotte Cunningham-Rundles; Lionel Galicier; Agnès Dechartres; Alice Berezne; Bernard Bonnotte; Thierry DeRevel; Christophe Auzary; Roland Jaussaud; Claire Larroche; Alain LeQuellec; Marc Ruivard; Pascal Seve; Amar Smail; Jean-François Viallard; Bertrand Godeau; Olivier Hermine; Marc Michel
Journal:  Br J Haematol       Date:  2011-10-08       Impact factor: 6.998

2.  Common variable immunodeficiency.

Authors:  Jonathan S Tam; John M Routes
Journal:  Am J Rhinol Allergy       Date:  2013 Jul-Aug       Impact factor: 2.467

3.  Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients.

Authors:  G K Wong; S Goldacker; C Winterhalter; B Grimbacher; H Chapel; M Lucas; D Alecsandru; D McEwen; I Quinti; H Martini; C Milito; R E Schmidt; D Ernst; T Espanol; A Vidaller; J Carbone; E Fernandez-Cruz; V Lougaris; A Plebani; N Kutukculer; L I Gonzalez-Granado; R Contreras; S Kiani-Alikhan; M A A Ibrahim; J Litzman; A Jones; H B Gaspar; L Hammarstrom; U Baumann; K Warnatz; A P Huissoon
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

4.  Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with Rituximab.

Authors:  Trine H Mogensen; Jens Magnus Bernth-Jensen; Charlotte C Petersen; Mikkel S Petersen; Charlotte Nyvold; Karsten H Gadegaard; Marianne Hokland; Peter Hokland; Carsten S Larsen
Journal:  BMC Hematol       Date:  2013-04-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.